250 related articles for article (PubMed ID: 24055406)
21. Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.
Li S; Li L; Zhu Y; Huang C; Qin Y; Liu H; Ren-Heidenreich L; Shi B; Ren H; Chu X; Kang J; Wang W; Xu J; Tang K; Yang H; Zheng Y; He J; Yu G; Liang N
Br J Cancer; 2014 May; 110(11):2812-20. PubMed ID: 24743704
[TBL] [Abstract][Full Text] [Related]
22. [Correlation between common driver gene variations and clinicopathological typing in lung adenocarcinoma].
Ma XL; Jia RN; Han K; Zhang YX
Zhonghua Bing Li Xue Za Zhi; 2024 Jun; 53(6):578-584. PubMed ID: 38825903
[No Abstract] [Full Text] [Related]
23. Epidermal growth factor receptor and KRAS mutations in lung adenocarcinoma: a retrospective study of the Lebanese population.
Fakhruddin N; Mahfouz R; Farhat F; Tfayli A; Abdelkhalik R; Jabbour M; Yehia L; Mahfoud Z; Zaatari G
Oncol Rep; 2014 Nov; 32(5):2223-9. PubMed ID: 25120214
[TBL] [Abstract][Full Text] [Related]
24. Cytomorphologic features of advanced lung adenocarcinomas tested for EGFR and KRAS mutations: a retrospective review of 50 cases.
Marotti JD; Schwab MC; McNulty NJ; Rigas JR; DeLong PA; Memoli VA; Tsongalis GJ; Padmanabhan V
Diagn Cytopathol; 2013 Jan; 41(1):15-21. PubMed ID: 21681971
[TBL] [Abstract][Full Text] [Related]
25. Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice.
Yamaguchi N; Vanderlaan PA; Folch E; Boucher DH; Canepa HM; Kent MS; Gangadharan SP; Majid A; Kocher ON; Goldstein MA; Huberman MS; Costa DB
Lung Cancer; 2013 Oct; 82(1):31-7. PubMed ID: 23932486
[TBL] [Abstract][Full Text] [Related]
26. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling.
Chaft JE; Arcila ME; Paik PK; Lau C; Riely GJ; Pietanza MC; Zakowski MF; Rusch V; Sima CS; Ladanyi M; Kris MG
Mol Cancer Ther; 2012 Feb; 11(2):485-91. PubMed ID: 22135231
[TBL] [Abstract][Full Text] [Related]
27. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
[TBL] [Abstract][Full Text] [Related]
28. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL
Oncology; 2015; 89(3):175-86. PubMed ID: 25833149
[TBL] [Abstract][Full Text] [Related]
29. EGFR and KRAS mutations in patients with adenocarcinoma of the lung.
Jang TW; Oak CH; Chang HK; Suo SJ; Jung MH
Korean J Intern Med; 2009 Mar; 24(1):48-54. PubMed ID: 19270482
[TBL] [Abstract][Full Text] [Related]
30. Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas.
Johnson ML; Sima CS; Chaft J; Paik PK; Pao W; Kris MG; Ladanyi M; Riely GJ
Cancer; 2013 Jan; 119(2):356-62. PubMed ID: 22810899
[TBL] [Abstract][Full Text] [Related]
31. Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: report on initial experience and clinical utility at a single center.
D'Angelo SP; Park B; Azzoli CG; Kris MG; Rusch V; Ladanyi M; Zakowski MF
J Thorac Cardiovasc Surg; 2011 Feb; 141(2):476-80. PubMed ID: 20933246
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer.
Li Y; Li Y; Yang T; Wei S; Wang J; Wang M; Wang Y; Zhou Q; Liu H; Chen J
PLoS One; 2013; 8(1):e52093. PubMed ID: 23341890
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathologic characteristics of ALK rearrangements in primary lung adenocarcinoma with identified EGFR and KRAS status.
Wang J; Dong Y; Cai Y; Zhou L; Wu S; Liu G; Su D; Li X; Qin N; Nong J; Jia H; Zhang Q; Mu J; Zeng X; Zhang H; Zhang S; Zhang Z
J Cancer Res Clin Oncol; 2014 Mar; 140(3):453-60. PubMed ID: 24442099
[TBL] [Abstract][Full Text] [Related]
34. Molecular spectrum of somatic EGFR and KRAS gene mutations in non small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel variations in Indian patients.
Das BR; Bhaumik S; Ahmad F; Mandsaurwala A; Satam H
Pathol Oncol Res; 2015 Jul; 21(3):675-87. PubMed ID: 25637496
[TBL] [Abstract][Full Text] [Related]
35. Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients.
Xia N; An J; Jiang QQ; Li M; Tan J; Hu CP
Exp Lung Res; 2013 Oct; 39(8):328-35. PubMed ID: 23919423
[TBL] [Abstract][Full Text] [Related]
36. EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity.
Yang Y; Yang Y; Zhou X; Song X; Liu M; He W; Wang H; Wu C; Fei K; Jiang G
Lung Cancer; 2015 Mar; 87(3):272-7. PubMed ID: 25582278
[TBL] [Abstract][Full Text] [Related]
37. Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas.
Wang R; Pan Y; Li C; Zhang H; Garfield D; Li Y; Ye T; Hu H; Luo X; Li H; Zhang Y; Zhang J; Zhou X; Shen L; Pao W; Sun Y; Chen H
J Thorac Oncol; 2014 Jun; 9(6):760-8. PubMed ID: 24481316
[TBL] [Abstract][Full Text] [Related]
38. Gene expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung adenocarcinoma.
Shibata T; Hanada S; Kokubu A; Matsuno Y; Asamura H; Ohta T; Sakamoto M; Hirohashi S
Cancer Sci; 2007 Jul; 98(7):985-91. PubMed ID: 17459062
[TBL] [Abstract][Full Text] [Related]
39. EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma.
Smits AJ; Kummer JA; Hinrichs JW; Herder GJ; Scheidel-Jacobse KC; Jiwa NM; Ruijter TE; Nooijen PT; Looijen-Salamon MG; Ligtenberg MJ; Thunnissen FB; Heideman DA; de Weger RA; Vink A
Cell Oncol (Dordr); 2012 Jun; 35(3):189-96. PubMed ID: 22528563
[TBL] [Abstract][Full Text] [Related]
40. Mitochondrial DNA mutations in respiratory complex-I in never-smoker lung cancer patients contribute to lung cancer progression and associated with EGFR gene mutation.
Dasgupta S; Soudry E; Mukhopadhyay N; Shao C; Yee J; Lam S; Lam W; Zhang W; Gazdar AF; Fisher PB; Sidransky D
J Cell Physiol; 2012 Jun; 227(6):2451-60. PubMed ID: 21830212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]